{"id":"W4410809399","doi":"10.1200/jco.2025.43.16_suppl.tps5118","title":"Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Amgen","keywords":"Cabazitaxel; Medicine; Taxane; Prostate cancer; Androgen receptor; Oncology; Androgen deprivation therapy; Internal medicine; Androgen; Cancer; Prostate; Gynecology; Breast cancer; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00313919,0.002629127,0.002356341,0.0005937885,0.0006200827,0.001959182,0.00176818,0.002902306,0.01169915],"category_scores_gemma":[0.001811531,0.0007947899,0.002513394,0.0004733173,0.001467143,0.001923405,0.0004930376,0.006693745,0.002248112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001051735,"about_ca_system_score_gemma":0.001836127,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001236871,"about_ca_topic_score_gemma":0.002669326,"domain_scores_codex":[0.9993154,0.0003724983,0.00002513053,0.000103113,0.00005670462,0.000127168],"domain_scores_gemma":[0.9987267,0.0002935135,0.0003104312,0.00009796018,0.00007759115,0.0004937799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9433739,0.02295643,0.0009535691,0.0005108665,0.0006561883,0.000095421,0.0001324978,0.0007669786,0.004233466,0.0003848304,0.003923571,0.0220123],"study_design_scores_gemma":[0.8593224,0.1353038,0.001585484,0.00003641494,0.000206308,0.0001240572,0.00004012924,0.0007664966,0.0006727847,0.0003176384,0.001605059,0.00001946254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9696664,0.005986652,0.001395166,0.002215658,0.0008427688,0.008110001,0.004897902,0.0005423898,0.006343181],"genre_scores_gemma":[0.9619636,0.003581366,0.003871972,0.003601786,0.0006404722,0.009685832,0.006036045,0.000137303,0.01048159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01169915,"threshold_uncertainty_score":0.03913754,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1740262717755847,"score_gpt":0.5335429345411211,"score_spread":0.3595166627655365,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}